China admits its Covid jabs are not very effective in major blow to global health battle

By | April 14, 2021

More proof UK won’t suffer devastating third Covid wave? China admits its jab rolled out in Chile doesn’t work well – confounding doomsayers who pointed to country’s third wave despite vaccine drive

  • Rare confession made by Director of the Chinese CDC, Gao Fu, last night   
  • He said Chinese vaccines ‘don’t have very high protection rates’ against Covid
  • Chile has ordered 60m doses of CoronaVac jab and has used it on 8m residents

China has admitted its Covid vaccines do not work well – which could explain why Chile is suffering a resurgence despite having one of the best rollouts in the world.

In an extremely rare confession, the head of the Chinese Centre for Disease Control and Prevention, Gao Fu, said the jabs ‘don’t have very high protection rates’ against coronavirus symptoms. They are being used in at least 45 countries.

He gave no specific details, but a University of Chile study found China’s CoronaVac jab was only 3 per cent effective in the 28 days between the first and second doses, rising to 56.5 per cent two weeks after the second dose. Mr Fu has since told state media that his comments were ‘completely misunderstood’.

Chile has ordered 60million doses of the vaccine, manufactured by Sinovac, and has fully vaccinated more than a fifth of its population with the jab.

It may explain why Chile is suffering a severe Covid surge, despite having one of the highest global vaccination rates. Almost 40 per cent of the nation’s 19million people have already been jabbed.

The development is significant because No10’s scientists in the UK had pointed to Chile as a cautionary tale for those looking to end lockdown sooner.

Chief medical officer Chris Whitty told a Downing Street press conference last week: ‘We want to do things in a steady way because the assumption that just because you vaccinate lots of people, then the problem goes away, I think Chile is quite a good corrective to that.’

Britain is using the Pfizer and AstraZeneca jabs which far outperformed the Chinese vaccines in clinical trials and appear to be just as effective in the real world.

Read More:  More than 1/3 of health organizations hit by ransomware last year, report finds

Analysis by Public Health England suggests they prevent more than 70 per cent of people becoming infected, and reduce deaths and hospital admissions by more than 90 per cent, after two doses.

China's admission may explain why Chile is suffering a severe Covid surge despite having one of the highest global vaccination rates

China’s admission may explain why Chile is suffering a severe Covid surge despite having one of the highest global vaccination rates

The director of the Chinese Centre for Disease Control and Prevention, Gao Fu, (pictured) said the vaccines made in China ‘don’t have very high protection rates’ against covid symptoms

The director of the Chinese Centre for Disease Control and Prevention, Gao Fu, (pictured) said the vaccines made in China ‘don’t have very high protection rates’ against covid symptoms

China has exported hundreds of millions of jabs made by state-owned firms mainly to Asia, Africa and Latin America, but also to Hungary and Turkey. 

Mr Gao revealed China, which has vaccinated around 160million people, was now considering using different jabs.

He said: ‘It’s now under formal consideration whether we should use different vaccines from different technical lines for the immunisation process.’

According to the Associated Press, vaccines made by two state-owned drugs firms, Sinovac and Sinopharm, have been exported to at least 45 countries, mainly in Asia, Africa and Latin America. 

These vaccines are based on an inactivated virus – a similar model to that used by the Oxford/AstraZeneca jab.

But they do not target the distinctive ‘spike’ protein of Covid.

Experts say that mixing vaccines, or increasing the number of doses, might boost effectiveness. 

Researchers in Britain are studying a possible combination of the Pfizer/BioNTech and Oxford/AstraZeneca vaccines.

The UAE recently experimented with administering three shots of China’s Sinopharm vaccine, instead of two, over reports of low numbers of antibodies.

The effectiveness of the Sinovac jab at preventing symptomatic infections after both doses was found to be as low as 50.4 per cent by researchers in Brazil. Trials showed Sinopharm’s vaccine was around 79 per cent effective.

Experts say mixing vaccines might boost their effectiveness. Researchers in Britain are studying a possible combination of the Pfizer/BioNTech and Oxford/AstraZeneca vaccines

Experts say mixing vaccines might boost their effectiveness. Researchers in Britain are studying a possible combination of the Pfizer/BioNTech and Oxford/AstraZeneca vaccines

By comparison, the Pfizer/BioNTech vaccine has been found to be 97 per cent effective.

Read More:  People with HIV aged 75 and older receiving good HIV care but many at risk of frailty

And study by the University of Chile found that efficacy in the 28 days between the first and second dose was only three per cent.  

Chilean science minister Andres Couve said it was important to focus on the data and the vaccine’s effectiveness in reducing illness that required medical treatment or being hospitalized or dying, which it achieved in the Brazilian study in 83.7 per cent and 100 per cent of cases, respectively.

He said Chile’s health ministry will shortly publish a real world study on the efficacy of both vaccines rolled out in its population and appealed to Chileans to continue to participate in the vaccination programme.

Heriberto Garcia, head of Chile’s Public Health Institute which approved CoronaVac’s emergency roll-out, said people should not pay attention to headlines.

‘The University of Chile study and the study the health ministry will release say the same thing: the number of people who fall ill and are hospitalized has decreased,’ he told local newspaper La Tercera. ‘We are going down the right path.’

British scientists told MailOnline as long as a month ago that a weak vaccine could be behind Chile’s spiralling cases.

Professor Ian Jones, a virologist at Reading University, said: ‘If half the population is vaccinated and the vaccine is 50 per cent effective (or less after one dose) then in effect the majority of the population was still susceptible, at least to infection, as the virus took off again.’

Yet some experts have still pointed to Chile as a warning that easing restrictions in the UK too soon could lead to another nasty virus surge. 

Sir David King, former chief scientific adviser to the Government, told Sky News today: ‘From the point of view of the population itself, we’re all dying to get out of lockdown.

‘From the point of view of the epidemic, I think it’s all a little bit more worrying.’

He added: ‘Chile is a country where the rate of vaccination amongst the population was third highest in the world – they were ahead of us in terms of the number of people who have had the vaccine – and they’re suddenly now into a third wave.

Read More:  Two-Thirds of Appendectomies May Be Unnecessary

‘They now have 7,600 cases a day and the total number of people in Chile now who have Covid is over a million.

‘So what has happened in Chile is very, very surprising – a high percentage of people have been vaccinated, but here’s a variant of the disease coming through the country.’

WHICH VACCINES ARE BRITAIN USING? AND HOW EFFECTIVE ARE THEY?

Pfizer-BioNTech

Approved: December 2, 2020

Doses dished out: 10.8million*

Doses ordered: 40million

Phase 3 trials data

  • Efficacy at blocking symptoms: 95%
  • Efficacy against severe illness: 100%

Real world data

  • Efficacy at stopping transmission: 66% 
  • Efficacy at blocking symptoms (one dose): Between 57 and 61% 
  • Efficacy against severe illness: 80%

How it works: mRNA vaccine – Genetic material from coronavirus is injected to trick the immune system into making ‘spike’ proteins and learning how to attack them.

Oxford-AstraZeneca

Approved: December 30, 2020

Doses dished out: 15.8million*

Doses ordered: 100million

Phase 3 trials data

  • Efficacy at blocking symptoms (one dose): 70% 
  • Efficacy against severe illness (one dose): 100%

Real world data

  • Efficacy at stopping transmission: 70% 
  • Efficacy at blocking symptoms: Between 60 and 73%
  • Efficacy against severe illness: 80% 

How it works: Adenovirus vaccine – To make the vaccine, the common cold virus is genetically modified to trigger it to make the Covid spike protein — which the virus uses to invade cells.

When the vaccine is administered the patient’s immune system attacks the spike protein by building antibodies, priming it to fight off Covid before it leads to an infection.

Moderna

Approved: January 8, 2021

Doses dished out: Zero

Doses ordered: 17million

Phase 3 trials data

  • Efficacy at blocking symptoms: 94.1% 
  • Efficacy against severe illness: 100%

Real world data

  • Efficacy at stopping transmission: Not known 
  • Efficacy at blocking symptoms: 90%** 
  • Efficacy against severe illness: Not known

How it works: mRNA vaccine – both Moderna’s and Pfizer and BioNTech’s vaccines work in the same way.

* the latest data goes up to March 21 

** data taken from a US study, joint with Pfizer. Other real world data comes from Public Health England in the UK 

Advertisement


Health News | Mail Online